{
    "clinical_study": {
        "@rank": "82271", 
        "arm_group": [
            {
                "arm_group_label": "Part A (single dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part B (multiple dose)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the safety,\n      tolerability and pharmacokinetics (the effect of the investigated drug on the body) of\n      single and multiple doses of a long-acting GLP-1 analogue (semaglutide) in an oral\n      formulation in healthy male subjects."
        }, 
        "brief_title": "Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subject, who is considered to be generally healthy, based on the medical\n             history, physical examination, and the results of vital signs, electrocardiogram\n             (ECG) and laboratory safety tests performed during the screening visit, as judged by\n             the investigator\n\n          -  Body Mass Index (BMI) between 20 and 30 kg/m^2\n\n          -  Glycosylated haemoglobin (HbA1c) below 6.0% (only in Part B)\n\n        Exclusion Criteria:\n\n          -  History of, or presence of, cancer, diabetes or any clinically significant\n             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal (GI),\n             endocrinological, haematological, dermatological, venereal, neurological, psychiatric\n             diseases or other major disorders, as judged by the investigator\n\n          -  Use of prescription or non-prescription medicinal and herbal products (except routine\n             vitamins) within three weeks preceding the dosing. Occasional use of paracetamol or\n             acetylsalicylic acid is permitted"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01866748", 
            "org_study_id": "NN9928-4048", 
            "secondary_id": [
                "2012-003199-38", 
                "U1111-1132-4190"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Part A (single dose)", 
                "description": "A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B (multiple dose)", 
                "description": "Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part A (single dose)", 
                "description": "In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B (multiple dose)", 
                "description": "In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 25, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "14050"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Part A: Number of treatment emergent adverse events (TEAEs)", 
                "safety_issue": "No", 
                "time_frame": "Day -1 to Day 24"
            }, 
            {
                "measure": "Part B: Number of treatment emergent adverse events (TEAEs)", 
                "safety_issue": "No", 
                "time_frame": "Recorded from the time of first dosing (Visit 3, Day -1 to day +2) and until completion of the post treatment follow-up visit (Visit 18, Day 90-104)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01866748"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part A: AUC0-24h,semaglutide: the area under the semaglutide plasma concentration curve", 
                "safety_issue": "No", 
                "time_frame": "From time 0 to 24 hours after a single dose (Day 0)"
            }, 
            {
                "measure": "Part B: AUC\u03c4,semaglutide: area under the semaglutide plasma concentration curve", 
                "safety_issue": "No", 
                "time_frame": "Over the dosing interval (0-24 hours) after the last 3 daily doses (Days 67-69)"
            }, 
            {
                "measure": "Part B: Change in fasting plasma glucose (FPG) from baseline", 
                "safety_issue": "No", 
                "time_frame": "Day 0 (pre-dose), day 70"
            }, 
            {
                "measure": "Part B: Change in body weight from baseline", 
                "safety_issue": "No", 
                "time_frame": "Day -1, day 70"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}